---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-022271"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-13T23:46:05.643016+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology's 2023 annual meeting results: all director nominees elected, BDO ratified, say-on-pay approved

## Summary
- Seven director nominees elected with votes ranging from 12.5M to 14.1M for; broker non-votes ~12.67M.
- Ratification of BDO USA as auditor for FY2023 approved with 26.56M for, 0.56M against, 0.18M abstain.
- Advisory vote on executive compensation frequency: 1-year option approved with 13.68M votes; board sets annual say-on-pay.
- Advisory vote on named executive officer compensation approved: 11.92M for, 2.42M against, 0.29M abstain.

## SEC filing metadata
- accession: 0001628280-23-022271
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/crdf-20230615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-022271
- JSON: https://secwatch.observer/filing/0001628280-23-022271.json
- Plain text: https://secwatch.observer/filing/0001628280-23-022271.txt

## Key facts
- Shareholder Votes
  Cardiff Oncology, Inc. shareholders approved Advisory vote on frequency of shareholder vote on named executive officer compensation at the 2023-06-15 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 3. A one year frequency of the advisory shareholder vote on the Company’s named executive officer compensation, as recommended by the Board of Directors, was approved by the stockholders by the votes set forth in the table below: 1 Year 2 Years 3 Years Abstain Broker Non Vote 13,681,338 142,222 696,088 108,422 12,671,079
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm
- Shareholder Votes
  Cardiff Oncology, Inc. shareholders approved Election of seven directors to serve until the 2024 Annual Meeting at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 1 . All of the seven (7) nominees for director were elected to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the seven (7) directors was as follows: Directors For Against Abstain Broker Non Vote Mark Erlander, Ph.D. 13,865,171 0 762,900 12,671,078 Dr. Rodney Markin 13,876,802 0 751,269 12,671,078 Dr. James O. Armitage 13,890,969 0 737,101 12,671,079 Lale White 13,785,160 0 842,910 12,671,079 Gary W. Pace, Ph.D. 14,140,640 0 487,431 12,671,078 Mani Mohindru, Ph.D. 12,545,020 0 2,083,050 12,671,079 Renee P. Tannenbaum, Pharm.D. 13,880,230 0 747,841 12,671,078
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm
- Shareholder Votes
  Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 4. The advisory vote on the compensation of the Company’s named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 11,916,210 2,419,195 292,665 12,671,079
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm
- Shareholder Votes
  Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: Proposal 2. The appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 26,560,889 560,805 177,454 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.